At the 2026 NCCN Annual Meeting, CURE sat down with Dr. Thomas Flaig to discuss the rapidly evolving landscape of bladder ...
FDA fast track designation supports expedited development and regulatory interaction for BBO-11818 in advanced KRAS-mutant ...
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to SIM0505 for the treatment of women with platinum resistant ovarian cancer (PROC) Phase 1 data for SIM0505 to be ...
With the introduction of mRNA vaccines in the 2010s – vaccines that use messenger RNA molecules in cells to train the body to ...
The FDA has granted fast track designation to a combination of lunresertib and zedoresertib for genomic-defined, platinum-resistant ovarian cancer, following encouraging phase 1 trial results. The ...
Fast Track status enables closer FDA engagement to potentially accelerate development of a CDH6-directed ADC in ...
JSKN003 has shown a 63% objective response rate and 7.7 months median progression-free survival in PROC patients, with higher efficacy in HER2-positive subgroups. The FDA's fast track designation ...
A research team in the Department of Pharmacology and Pharmacy at the LKS Faculty of Medicine of the University of Hong Kong (HKUMed), has conducted a pioneering study that found an association ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results